Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Summary

A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Testing includes 2 MRI scans, 2 glucose challenges, and 2 insulin withdrawal challenges along with physical assessments and vitals.

Timeline

Start

2019-07-01

Primary completion

2021-07-31

Completion

2022-05-31

Drugs

Indications